Assessment of the Glucose Management Indicator Using Different Sampling Durations
We compared the glucose management indicator (GMI) calculated using 14 days of continuous glucose monitor (CGM) data with GMI calculated using
Gespeichert in:
| Veröffentlicht in: | Diabetes technology & therapeutics 2023-02, Vol.25 (2), p.148-150 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 150 |
|---|---|
| container_issue | 2 |
| container_start_page | 148 |
| container_title | Diabetes technology & therapeutics |
| container_volume | 25 |
| creator | Bailey, Ryan Calhoun, Peter Bergenstal, Richard M Beck, Roy W |
| description | We compared the glucose management indicator (GMI) calculated using 14 days of continuous glucose monitor (CGM) data with GMI calculated using |
| doi_str_mv | 10.1089/dia.2022.0284 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2716935080</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2716935080</sourcerecordid><originalsourceid>FETCH-LOGICAL-c251t-81de3eaf65b462cb9bb4585c30a80d8931bebd2a3701d17fa78617759f2a5e973</originalsourceid><addsrcrecordid>eNqFkD1PwzAQhi0EglIYWVEkFpYUf9SxPVYFSiUQQtA5spMLuErsYicD_56kLQwsTHe699Gr04PQBcETgqW6Ka2eUEzpBFM5PUAjwrlIJVfscNgpThXh2Qk6jXGNMRaMkmN0wjLCMGFyhF5mMUKMDbg28VXSfkCyqLvCR0ietNPvsE2WrrSFbn1IVtG69-TWVhWEIXnVzabenrqgW-tdPENHla4jnO_nGK3u797mD-nj82I5nz2mBeWkTSUpgYGuMm6mGS2MMmbKJS8Y1hKXUjFiwJRUM4FJSUSlhcyIEFxVVHNQgo3R9a53E_xnB7HNGxsLqGvtwHcxp4JkinEscY9e_UHXvguu_66nBGFc8WwoTHdUEXyMAap8E2yjw1dOcD64znvX-eA6H1z3_OW-tTMNlL_0j9weYDtgOGvnagsGQvtP7TcUrYpB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2771359567</pqid></control><display><type>article</type><title>Assessment of the Glucose Management Indicator Using Different Sampling Durations</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Bailey, Ryan ; Calhoun, Peter ; Bergenstal, Richard M ; Beck, Roy W</creator><creatorcontrib>Bailey, Ryan ; Calhoun, Peter ; Bergenstal, Richard M ; Beck, Roy W</creatorcontrib><description>We compared the glucose management indicator (GMI) calculated using 14 days of continuous glucose monitor (CGM) data with GMI calculated using <14 days. Analysis included 581 individuals with type 1 diabetes or type 2 diabetes from five clinical trials. The correlation between the 14- and 7-day GMI was 0.95 and the correlation between 14 days versus 10, 5, and 3 days GMI was 0.98, 0.91, and 0.86, respectively. The percentages of GMI values within 0.3% of the 14-day GMI were 98% with 10-day GMI, 87% with 7-day GMI, 77% with 5-day GMI, and 60% with 3-day GMI. Minimal differences were observed between GMI computed using 14 days of data compared with GMI computed with 7 days. Although 10–14 days of CGM data are preferred for computing GMI, for most patients a satisfactory estimate of HbA1c can be obtained with 7 days of data.</description><identifier>ISSN: 1520-9156</identifier><identifier>EISSN: 1557-8593</identifier><identifier>DOI: 10.1089/dia.2022.0284</identifier><identifier>PMID: 36130138</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc., publishers</publisher><subject>Blood Glucose ; Blood Glucose Self-Monitoring ; Brief Reports ; Clinical trials ; Data analysis ; Diabetes ; Diabetes Mellitus, Type 1 - drug therapy ; Diabetes Mellitus, Type 2 - drug therapy ; Glucose ; Glucose monitoring ; Humans</subject><ispartof>Diabetes technology & therapeutics, 2023-02, Vol.25 (2), p.148-150</ispartof><rights>2023, Mary Ann Liebert, Inc., publishers</rights><rights>Copyright Mary Ann Liebert, Inc. Feb 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c251t-81de3eaf65b462cb9bb4585c30a80d8931bebd2a3701d17fa78617759f2a5e973</cites><orcidid>0000-0002-5194-8446 ; 0000-0001-5763-4598 ; 0000-0002-5325-7200 ; 0000-0002-9050-5584</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36130138$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bailey, Ryan</creatorcontrib><creatorcontrib>Calhoun, Peter</creatorcontrib><creatorcontrib>Bergenstal, Richard M</creatorcontrib><creatorcontrib>Beck, Roy W</creatorcontrib><title>Assessment of the Glucose Management Indicator Using Different Sampling Durations</title><title>Diabetes technology & therapeutics</title><addtitle>Diabetes Technol Ther</addtitle><description>We compared the glucose management indicator (GMI) calculated using 14 days of continuous glucose monitor (CGM) data with GMI calculated using <14 days. Analysis included 581 individuals with type 1 diabetes or type 2 diabetes from five clinical trials. The correlation between the 14- and 7-day GMI was 0.95 and the correlation between 14 days versus 10, 5, and 3 days GMI was 0.98, 0.91, and 0.86, respectively. The percentages of GMI values within 0.3% of the 14-day GMI were 98% with 10-day GMI, 87% with 7-day GMI, 77% with 5-day GMI, and 60% with 3-day GMI. Minimal differences were observed between GMI computed using 14 days of data compared with GMI computed with 7 days. Although 10–14 days of CGM data are preferred for computing GMI, for most patients a satisfactory estimate of HbA1c can be obtained with 7 days of data.</description><subject>Blood Glucose</subject><subject>Blood Glucose Self-Monitoring</subject><subject>Brief Reports</subject><subject>Clinical trials</subject><subject>Data analysis</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Glucose</subject><subject>Glucose monitoring</subject><subject>Humans</subject><issn>1520-9156</issn><issn>1557-8593</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkD1PwzAQhi0EglIYWVEkFpYUf9SxPVYFSiUQQtA5spMLuErsYicD_56kLQwsTHe699Gr04PQBcETgqW6Ka2eUEzpBFM5PUAjwrlIJVfscNgpThXh2Qk6jXGNMRaMkmN0wjLCMGFyhF5mMUKMDbg28VXSfkCyqLvCR0ietNPvsE2WrrSFbn1IVtG69-TWVhWEIXnVzabenrqgW-tdPENHla4jnO_nGK3u797mD-nj82I5nz2mBeWkTSUpgYGuMm6mGS2MMmbKJS8Y1hKXUjFiwJRUM4FJSUSlhcyIEFxVVHNQgo3R9a53E_xnB7HNGxsLqGvtwHcxp4JkinEscY9e_UHXvguu_66nBGFc8WwoTHdUEXyMAap8E2yjw1dOcD64znvX-eA6H1z3_OW-tTMNlL_0j9weYDtgOGvnagsGQvtP7TcUrYpB</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Bailey, Ryan</creator><creator>Calhoun, Peter</creator><creator>Bergenstal, Richard M</creator><creator>Beck, Roy W</creator><general>Mary Ann Liebert, Inc., publishers</general><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5194-8446</orcidid><orcidid>https://orcid.org/0000-0001-5763-4598</orcidid><orcidid>https://orcid.org/0000-0002-5325-7200</orcidid><orcidid>https://orcid.org/0000-0002-9050-5584</orcidid></search><sort><creationdate>20230201</creationdate><title>Assessment of the Glucose Management Indicator Using Different Sampling Durations</title><author>Bailey, Ryan ; Calhoun, Peter ; Bergenstal, Richard M ; Beck, Roy W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c251t-81de3eaf65b462cb9bb4585c30a80d8931bebd2a3701d17fa78617759f2a5e973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Blood Glucose</topic><topic>Blood Glucose Self-Monitoring</topic><topic>Brief Reports</topic><topic>Clinical trials</topic><topic>Data analysis</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Glucose</topic><topic>Glucose monitoring</topic><topic>Humans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bailey, Ryan</creatorcontrib><creatorcontrib>Calhoun, Peter</creatorcontrib><creatorcontrib>Bergenstal, Richard M</creatorcontrib><creatorcontrib>Beck, Roy W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes technology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bailey, Ryan</au><au>Calhoun, Peter</au><au>Bergenstal, Richard M</au><au>Beck, Roy W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of the Glucose Management Indicator Using Different Sampling Durations</atitle><jtitle>Diabetes technology & therapeutics</jtitle><addtitle>Diabetes Technol Ther</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>25</volume><issue>2</issue><spage>148</spage><epage>150</epage><pages>148-150</pages><issn>1520-9156</issn><eissn>1557-8593</eissn><abstract>We compared the glucose management indicator (GMI) calculated using 14 days of continuous glucose monitor (CGM) data with GMI calculated using <14 days. Analysis included 581 individuals with type 1 diabetes or type 2 diabetes from five clinical trials. The correlation between the 14- and 7-day GMI was 0.95 and the correlation between 14 days versus 10, 5, and 3 days GMI was 0.98, 0.91, and 0.86, respectively. The percentages of GMI values within 0.3% of the 14-day GMI were 98% with 10-day GMI, 87% with 7-day GMI, 77% with 5-day GMI, and 60% with 3-day GMI. Minimal differences were observed between GMI computed using 14 days of data compared with GMI computed with 7 days. Although 10–14 days of CGM data are preferred for computing GMI, for most patients a satisfactory estimate of HbA1c can be obtained with 7 days of data.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc., publishers</pub><pmid>36130138</pmid><doi>10.1089/dia.2022.0284</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-5194-8446</orcidid><orcidid>https://orcid.org/0000-0001-5763-4598</orcidid><orcidid>https://orcid.org/0000-0002-5325-7200</orcidid><orcidid>https://orcid.org/0000-0002-9050-5584</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1520-9156 |
| ispartof | Diabetes technology & therapeutics, 2023-02, Vol.25 (2), p.148-150 |
| issn | 1520-9156 1557-8593 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2716935080 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Blood Glucose Blood Glucose Self-Monitoring Brief Reports Clinical trials Data analysis Diabetes Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 2 - drug therapy Glucose Glucose monitoring Humans |
| title | Assessment of the Glucose Management Indicator Using Different Sampling Durations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T16%3A09%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20the%20Glucose%20Management%20Indicator%20Using%20Different%20Sampling%20Durations&rft.jtitle=Diabetes%20technology%20&%20therapeutics&rft.au=Bailey,%20Ryan&rft.date=2023-02-01&rft.volume=25&rft.issue=2&rft.spage=148&rft.epage=150&rft.pages=148-150&rft.issn=1520-9156&rft.eissn=1557-8593&rft_id=info:doi/10.1089/dia.2022.0284&rft_dat=%3Cproquest_cross%3E2716935080%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2771359567&rft_id=info:pmid/36130138&rfr_iscdi=true |